Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147914 | 0.89 | CYP46A1 (0.48) | CYP46A1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20070184 | 0.84 | CYP46A1 (0.56) | CYP46A1GRIN2BPKLRRETLMNA | |
| SCHEMBL20147391 | 0.82 | CYP2D6 (0.42) | OPRM1CYP2D6RETLMNAGAA | |
| SCHEMBL25502398 | 0.81 | CYP46A1 (0.55) | CYP46A1GRIN2BPKLRRETLMNA | |
| SCHEMBL16051233 | 0.80 | CYP46A1 (0.50) | CYP46A1OPRM1GRIN2BPKLRRET | |
| SCHEMBL25499870 | 0.79 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL20069495 | 0.79 | PKLR (0.43) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL27967306 | 0.78 | CYP46A1 (0.63) | CYP46A1GRIN2BPKLRLMNAGAA | |
| SCHEMBL14840378 | 0.78 | CYP46A1 (0.54) | CYP46A1GRIN2BPKLRRETLMNA | |
| SCHEMBL9963238 | 0.77 | OPRL1 (0.69) | OPRM1OPRD1OPRK1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190263811-A1 | CRYSTALLINE FORMS | ARRAY BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2019075108-A1 | CRYSTALLINE FORMS | METCALF ANDREW T (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-20190263811-A1 | CRYSTALLINE FORMS | RET, ALK, ROR1 | CYP46A1 3708/4885OPRM1 3559/4885OPRD1 3932/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CYP46A1 4055/4885OPRM1 3497/4885OPRD1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.